Trine
Trine Aakvik, Trondheim NO
Patent application number | Description | Published |
---|---|---|
20100227779 | PLASMID RK2-BASED BROAD-HOST-RANGE CLONING VECTOR USEFUL FOR TRANSFER OF METAGENOMIC LIBRARIES TO A VARIETY OF BACTERIAL SPECIES - The present invention relates to a cloning vector for cloning of DNA in a broad host range of bacteria, the vector being an autonomously replicating artificial chromosome comprising: (i) the RK2 origin of replication oriV; (ii) the RK2 origin of conjugate transfer oriT; (iii) par DE from RK2; (iv) a cloning region; (v) a further origin of replication which permits replication of said vector at a copy number of no more than 1 or 2; wherein the vector is no more than 15 kb in size, does not contain trfA of RK2, and is capable of cloning inserts of at least 12 kb and wherein the content of RK2 DNA in the vector is no more than 10% of RK2. The invention also relates to host cells and a vector system having the cloning vector. Methods of cloning DNA and preparing a library and uses of the vector and the RK2 replicon in metagenomic cloning are provided. | 09-09-2010 |
Trine Ahlgreen, Frederiksberg C DK
Patent application number | Description | Published |
---|---|---|
20160058840 | Novel Administration Regime - The invention relates to a novel administration regime useful in the treatment of diseases or conditions where administration of insulin will be of benefit, as well as to kits for use in the same. In particular, the invention relates to a long-acting or ultra-long acting insulin for use in treating a disease or condition where administration of insulin will be of benefit, wherein the administration of said insulin comprises or consists of the following steps: (a) optionally providing a blood sample to be tested from an individual in need of treatment; (b) taking a single fasting blood (or plasma) glucose measurement from said individual in need of treatment; (c) using the single fasting blood (or plasma) glucose measurement to determine the insulin dose to be administered; and (d) administering the long-acting or ultra-long insulin to the individual at the dose determined in step (c). | 03-03-2016 |
Trine Kirkhus, Oslo NO
Patent application number | Description | Published |
---|---|---|
20120243374 | ACOUSTIC MOTION DETERMINATION - The motion of an object is characterised by transmitting acoustic signals over first and second transmitter-receiver channels. Information relating to signals received over the first channel is compared with information relating to signals received over the second channel, to identify a similar pattern in both channels arising from reflections from the object. A relative timing difference between the channels, associated with the similar pattern, is used to characterise the motion of the object. | 09-27-2012 |
Trine Klemensø, Roskilde DK
Patent application number | Description | Published |
---|---|---|
20140010953 | SINTERING ADDITIVES FOR CERAMIC DEVICES OBTAINABLE IN A LOW pO2 ATMOSPHERE - The present invention provides a method for producing a ceramic device in a low pO | 01-09-2014 |
Trine Sorensen, Copenhagen DK
Patent application number | Description | Published |
---|---|---|
20160046917 | Cellobiohydrolase Variants and Polynucleotides Encoding Same - The present invention relates to cellobiohydrolase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants. | 02-18-2016 |
Trine Staalso, Copenhagen DK
Patent application number | Description | Published |
---|---|---|
20090324628 | COMPOUNDS USEFUL IN THE DIAGNOSIS AND TREATMENT OF MALARIA - The present invention relates to nucleic acid molecules related to the PFD1235w/MAL7P1.1, PF11_0008, and PF13_0003 gene families as well as amino acid sequences encoded by such nucleic acid molecules with respect to their role in mediating adhesion of infected red blood cells to endothelial cells, which is characteristic for the pathogenesis of severe malaria (SM). Accordingly, the invention provides pharmaceutical compositions and vaccines, hereunder nucleotide-based vaccines comprising compounds that are related to VAR4, VAR5, and/or VAR6 polypeptides and PFD1235w/MAL7P1.1 PF11_0008, and/or PF13_0003 nucleic acid molecules. The invention further relates to the use of these compounds as medicaments and for the manufacture of compositions, such as immunogenic compositions. In addition, the invention relates to methods of treatment and prevention of severe malaria wherein these methods are based on the nucleic acid molecules and polypeptides of the invention. As these compounds can also be used as biotechnological tools the invention provides in vitro diagnostic methods and kits comprising reagents and IgGs/antibodies designated to the use in such methods. The invention also relates to methods of identifying agents capable of modulating the VAR4, VAR5, and/or VAR6 dependent adhesion to endothelial cells and agent capable of interacting with VAR4, VAR5, and/or VAR6. Finally, a method for identifying polypeptides, which will induce a specific IgG/antibody response upon administration to a subject is provided by the invention. | 12-31-2009 |
Trine Trugvason, Lem St. DK
Patent application number | Description | Published |
---|---|---|
20140051831 | METHOD FOR ISOLATING OSTEOPONTIN USING FEEDS CONTAINING CMP OR CASEIN SPECIES - The present invention pertains to a method for isolating osteopontin from a milk-derived feed containing caseino macropeptide and/or free beta casein, such as e.g. a feed based on milk serum or sweet whey. Particularly, the present method involves the use of a narrow window of pH and specific conductance of the milk-derived feed, which surprisingly has proven to provide a very efficient isolation of osteopontin from chemically complex feeds. | 02-20-2014 |
20140066607 | METHOD FOR ISOLATING OSTEOPONTIN USING CONCENTRATED FEEDS - The present invention pertains to a method for isolating osteopontin from milk-derived feeds having a high concentration of protein. Particularly, the present method involves the use of a narrow window of pH and specific conductance of the milk-derived feed, which surprisingly has proven to provide a very efficient isolation of osteopontin from chemically complex feeds. | 03-06-2014 |